The neuropathological assessment of amyloid in brain parenchyma (CERAD score) and vasculature (CAA) as well as tau accumulation (Braak staging) in the brain guided the classification of cases as neurologically healthy controls (Emory: N=20; UPenn: N=25) or Alzheimer’s disease (Emory: 61; UPenn: N=12). This evidence concerns the gene MAPT and amyloidosis.